Cascadian Therapeutics
Sep 20, 2017

Cascadian Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference

SEATTLE, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that management will present at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017, at 9:45 a.m. EDT / 6:45 a.m. PDT in New York City.

A live audio webcast of the presentation will be available through the "Events & Presentations" page of the "News & Events" section of Cascadian Therapeutics' website at An archived edition of the session will be available later that day.

About Cascadian Therapeutics

Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib, is an investigational oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind, controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab, in patients with locally advanced or metastatic HER2+ breast cancer with and without brain metastases, who have previously been treated with trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at or For more information, please visit

Investor and Media Contact:
Monique Greer
Cascadian Therapeutics